Antibody-drug conjugates for the treatment of ovarian cancer

Introduction Ovarian cancer typically presents at an advanced stage and while initial chemotherapy response rates are favorable, a majority of patients experience recurrence with the subsequent development of chemoresistance. Recurrent, platinum-resistant disease is associated with a very poor prognosis as treatment in this setting is often limited by systemic toxicity. Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target antigens specific to ovarian tumor cells with direct delivery of cytotoxic agents to combat recurrent, platinum-resistant disease while limiting systemic toxicity. Areas covered The basic structure and function of ADCs will be reviewed as well as the current data on ADCs under investigation in ovarian cancer. Expert opinion ADCs represent a promising class of targeted therapy in recurrent ovarian cancer with excellent response rates particularly when utilized as combination therapy. While mirvetuximab soravtansine is the only ADC that has been evaluated in a phase 3 trial, many other ADCs and trials are on the horizon. As the field of targeted therapy continues to evolve, continued development of target antigens and ADCs are likely to represent a key development in treatment of recurrent, platinum-resistant disease.

Automated summary

ADCs offer promising targeted therapy in recurrent ovarian cancer with excellent response rates, especially when used in combination therapy. While mirvetuximab soravtansine is the only ADC evaluated in a phase 3 trial, numerous other ADCs and trials are emerging in the field. Continued development of target antigens and ADCs are likely to play a key role in treating recurrent, platinum-resistant disease.